UroGen Pharma Ltd. (URGN)
URGNNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$25.32
-1.31 (-4.92%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $1.24bn
- P/E
- –
- EPS, last 4 quarters
- $-1.32
- Dividend yield
- –
- Day range
- –
- 52-week range
- $16.50 to $50.81
- Average volume
- 1.03m
- Previous close
- $26.63
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $62.20, +145.7% from here
Earnings
next estimate $0.4100Next report
Dec 2025
+18.2%
Mar 2026
+16.1%
Jun 2026
+26.3%
Sep 2026
-160.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $37.84m | $50.96m | $72.46m | $89.00m |
| Gross profit | $34.55m | $46.82m | $65.88m | $81.50m |
| Operating income | -$19.11m | -$20.26m | $111.0k | $8.33m |
| Net income | -$26.36m | -$23.57m | -$14.35m | -$1.46m |
Last four quarters: revenue $250.25m, margin -26.3%, free cash flow -$132.05m
News
8 latest- Urogen Pharma Q3 Earnings Call HighlightsMarketBeat · 6 days ago
- The Gel That Became a BusinessThe Motley Fool · 6 days ago
- UroGen (URGN) Q3 2026 Earnings Call TranscriptThe Motley Fool · 6 days ago
- UroGen Pharma Ltd. Reports Third Quarter 2026 Financial Results and FDA Acceptance of UGN-103 NDAFintel · 6 days ago
- UroGen Pharma Reports $68 Mln In Q3 ZUSDURI Sales; Sets UGN-103 FDA Date; Shares Down RTTNews · 6 days ago
- Urogen Pharma (URGN) Reports Q3 Loss, Beats Revenue EstimatesZacks · 7 days ago
- UroGen Initiates Phase 1 Trial Of Next-Generation Bladder Cancer Therapy UGN-501 RTTNews · Nov 2, 2026
- Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks · Oct 29, 2026
The company
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first product is approved to treat low-grade upper tract urothelial cancer, and UroGen's second product is approved for adult patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- Middle East
- Website
- urogen.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.